
What smart money is saying about Becton, Dickinson and Company
11 funds in our archive have pitched Becton, Dickinson and Company — most recently 1578 Partners, LP in March 2026.
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q2 2026, 8 fund letters reported a position in Becton, Dickinson and Company — 3 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 2 | 0 | 1 | 0 |
| Q1 2026 | 6 | 3 | 0 | 3 |
| Q3 2025 | 0 | 0 | 0 | 3 |
| Q2 2025 | 0 | 0 | 0 | 3 |
| Q4 2024 | 0 | 0 | 0 | 2 |
Fund activity · 8 positions · 4 moves
- HoldsClearBridge Investments Dividend StrategyJune 2026
“We also exited the small position in Waters we had received following its spinoff from Becton Dickinson in the first quarter.”
Read the letterBecton, Dickinson and Company - ExitedClearBridge Investments Value StrategyJune 2026
“We exited positions in Becton Dickinson and UCB in the health care sector, Webster Financial, MGIC Investment and Ryan Specialty Holdings in the financials sector, American Homes 4 Rent in the real estate sector and TFI International in the industrials sector.”
Read the letterBecton, Dickinson and Company - New positionBA Beutel Goodman U.S. Value FundMarch 2026
“We added several new positions during the quarter: Union Pacific, Sysco, Wells Fargo, Beckton Dickinson and Marsh & McLennan.”
Read the letterBecton, Dickinson and Company - New positionBrown Advisory Large-Cap Sustainable ValueMarch 2026
“We also established a new position in Becton, Dickinson, & Co (BDX) ahead of the company combining its Biosciences & Diagnostics business with Waters Corporation (WAT) through a Reverse Morris Trust.”
Read the letterBecton, Dickinson and Company - New positionBA Beutel Goodman World Value FundMarch 2026
“During the quarter, we initiated positions in Union Pacific, Brookfield Asset Management, Sysco and Becton Dickinson.”
Read the letterBecton, Dickinson and Company - HoldsHardman Johnston Large Cap EquityMarch 2026
“AstraZeneca plc United Kingdom 1.0 Pharmaceuticals Becton, Dickinson & Co. United States 1.1 Health Care Equipment & Supplies”
Read the letterBecton, Dickinson and Company - Holds1578 Partners, LPMarch 2026
“This quarter’s portfolio update covers our position in Becton, Dickinson and Company common stock (NYSE: BDX).”
Read the letterBecton, Dickinson and Company - HoldsHardman Johnston Select EquityMarch 2026
“Becton, Dickinson & Co. United States 1.4 Health Care Equipment & Supplies”
Read the letterBecton, Dickinson and Company
Fund coverage · 11 theses
- 1578 Partners, LPMarch 2026
Becton Dickinson is a diversified medical supplies and devices company with resilient demand, margin expansion potential, strong free cash flow conversion, and share buybacks supporting intrinsic value growth.
Read the full thesis - Brown Advisory Large-Cap Sustainable ValueMarch 2026
Becton, Dickinson has a dominant consumables franchise, high market share, and an attractive valuation after the divestiture.
Read the full thesis - Brown Advisory U.S. Value FundMarch 2026
Becton, Dickinson and Company has a non-discretionary consumables franchise, leading market share, and attractive valuation after a divestiture.
Read the full thesis - Schafer Cullen ESG Value Equity StrategySeptember 2025
Becton Dickinson is a global medical technology provider poised for consistent mid-single-digit growth, with upcoming product launches and a strategic business separation expected to enhance its market position and profitability.
Read the full thesis - Hinde GroupSeptember 2025
Becton, Dickinson and Company is an attractive special situation investment poised for value unlocking through a spin-off and merger with Waters Corporation, anticipated to enhance its stock valuation significantly.
Read the full thesis - Fiduciary ManagementSeptember 2025
Becton Dickinson is a leading medical supply company poised for growth and value unlocking through strategic simplification and a strong focus on recurring revenue.
Read the full thesis - Heartland Opportunistic Value Equity StrategyJune 2025
BDX is undervalued at a 20% discount to healthcare peers, despite its strong position in the market and potential for growth amid recent challenges.
Read the full thesis - Schafer Cullen High Dividend ValueJune 2025
Becton Dickinson is a global medical technology company with a strong market position, currently trading at a low P/E ratio, presenting growth opportunities despite recent headwinds.
Read the full thesis - Harris Oakmark Global Concentrated StrategyJune 2025
Becton, Dickinson and Company is a high-quality medical technology firm offering essential products, currently undervalued due to short-term market pressures, presenting a buying opportunity for long-term growth.
Read the full thesis - AMG River Road Large Cap Value Select FundDecember 2024
Becton, Dickinson and Company is a diversified medical technology leader with a strong focus on recurring revenue, high growth markets, and a solid history of dividend increases, despite recent underperformance and elevated leverage.
Read the full thesis - Generation IMDecember 2024
Becton Dickinson is a stable US medical device company with a 60% market share
Read the full thesis
Read every full thesis on Becton, Dickinson and Company
Unlock all 11 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→